Although association of serum IL-6 with response to ICIs has yet to be shown, CRP, whose production is mainly controlled by IL-6 (107), has been reported to be predictive of outcomes in patients treated with ICIs, which bolsters the argument of IL-6 as a potential biomarker of anti-tumor response during ICI treatment. Here, IL6 is linked to neoplasm.